Indeed, deletion of IRF5 protected mice from development of bleomycin-induced skin and pulmonary fibrosis (50), which makes IRF5 a potential therapeutic target in systemic sclerosis and scleroderma. This evidence concerns the gene IRF5 and pulmonary fibrosis.